Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares fell 1.6% during mid-day trading on Tuesday following insider selling activity. The company traded as low as $6.68 and last traded at $6.76. 882,144 shares were traded during trading, a decline of 84% from the average session volume of 5,688,068 shares. The stock had previously closed at $6.87.
Specifically, COO Tina Marriott sold 6,000 shares of the company's stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $6.31, for a total transaction of $37,860.00. Following the transaction, the chief operating officer now owns 521,138 shares in the company, valued at $3,288,380.78. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Analyst Upgrades and Downgrades
RXRX has been the subject of several recent research reports. Leerink Partners dropped their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a report on Tuesday, September 3rd. Needham & Company LLC dropped their price objective on Recursion Pharmaceuticals from $16.00 to $11.00 and set a "buy" rating for the company in a report on Wednesday, September 4th. KeyCorp dropped their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an "overweight" rating for the company in a report on Thursday, July 11th. Finally, Jefferies Financial Group dropped their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a report on Tuesday, September 3rd. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Recursion Pharmaceuticals presently has a consensus rating of "Hold" and a consensus price target of $9.40.
Read Our Latest Report on RXRX
Recursion Pharmaceuticals Trading Down 1.9 %
The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $1.89 billion, a P/E ratio of -4.16 and a beta of 0.80. The business has a 50 day moving average price of $6.71 and a 200 day moving average price of $7.68.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.05). The company had revenue of $14.42 million during the quarter, compared to the consensus estimate of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The business's revenue was up 30.9% compared to the same quarter last year. During the same period last year, the company earned ($0.38) earnings per share. Analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current year.
Institutional Trading of Recursion Pharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of RXRX. Vanguard Group Inc. grew its position in shares of Recursion Pharmaceuticals by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 15,665,210 shares of the company's stock valued at $154,459,000 after purchasing an additional 158,376 shares during the period. Sumitomo Mitsui Trust Holdings Inc. grew its position in shares of Recursion Pharmaceuticals by 12.6% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,362,803 shares of the company's stock valued at $103,317,000 after purchasing an additional 1,159,023 shares during the period. Azzad Asset Management Inc. ADV acquired a new position in shares of Recursion Pharmaceuticals in the 1st quarter valued at approximately $161,000. Janney Montgomery Scott LLC acquired a new position in shares of Recursion Pharmaceuticals in the 1st quarter valued at approximately $310,000. Finally, Capstone Investment Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals in the 1st quarter valued at approximately $161,000. 89.06% of the stock is owned by institutional investors.
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Read More
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
